New hope for tough lymphoma: targeted pill shows promise in trial
NCT ID NCT05068440
First seen Mar 27, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This study tested a drug called zanubrutinib in 65 adults with a hard-to-treat type of lymphoma (DLBCL) that has a specific gene change (CD79B mutation) and has come back or not responded to prior treatment. Participants took the drug as a pill and were monitored for tumor shrinkage and side effects. The goal was to see if this targeted approach can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital
Hefei, Anhui, 230088, China
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 100050, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Guangdong Provincial Peoples Hospital Huifu Branch
Guangzhou, Guangdong, 510120, China
-
Hainan Cancer Hospital
Haikou, Hainan, 570312, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Institute of Hematology and Hospital of Blood Disease
Tianjin, Tianjin Municipality, 300020, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013, China
-
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
Taizhou Hospital of Zhejiang
Taizhou, Zhejiang, 317000, China
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510120, China
-
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, 330006, China
-
The First Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, 515041, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
-
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650100, China
-
Zhejiang University College of Medicine Second Affiliated Hospital
Hangzhou, Zhejiang, 310009, China
Conditions
Explore the condition pages connected to this study.